I’m Adam Walker a Biometrics consultant, and this is the Pharma Prescribed Podcast—where leaders, innovators, and hidden voices in healthcare open up. No soundbites. No spin. Just raw insight—one prescription at a time.

In an industry driven by data, protocols, and pressure, we rarely pause to ask the human questions: What drives us? What breaks us? And what truths live behind the titles we wear?

Leigh Fell—a trailblazer in clinical research, a champion of corporate wellbeing, and the visionary founder of Caritas Science Solutions. Leigh’s journey from managing oncology trials to building a purpose-driven CRO is a masterclass in blending scientific rigor with human-centered leadership.

With a degree in Physiology, Sport Science & Nutrition from the University of Glasgow, Leigh began her career running clinical trials for cancer therapies.

In 2017, she launched Caritas with a bold mission: to create a company that not only advances medicine but also nurtures its people. Today, Caritas specializes in trials for brain disorders and oncology, partnering with pharma innovators to address areas of profound unmet need.

Leigh’s leadership philosophy—what she calls corporate athleticism—has led to a 30% increase in employee retention and a culture where wellness and performance go hand in hand.

That ethos earned her a place in The Sunday Times feature on “25 Women Succeeding in 2025”—a spotlight on visionary leaders shaping the future of business, science, and society with purpose and resilience.

But Leigh’s impact goes beyond metrics. She’s redefining what it means to lead in life sciences: integrating yoga, marathon training, and mindfulness into the rhythm of business. Her belief? That building a company is like training for endurance—requiring discipline, resilience, and heart.

I’m Adam Walker a Biometrics consultant, and this is the Pharma Prescribed Podcast—where leaders, innovators, and hidden voices in healthcare open up. No soundbites. No spin. Just raw insight—one prescription at a time.

In an industry driven by data, protocols, and pressure, we rarely pause to ask the human questions: What drives us? What breaks us? And what truths live behind the titles we wear?

Anders Mortin is a seasoned eClinical professional with over two decades of experience in Clinical Development processes and systems.

Known for his strategic vision and leadership, Anders excels in managing cross-functional teams and driving innovative solutions.

As a co-founder of the Copenhagen-based pharma consulting firm, TriTiCon, established in 2015, he has been instrumental in shaping the company's success.

Anders holds a Master's degree in Engineering Physics from Lund University in Sweden and has been a key player in the industry since the early 90’s.

His extensive background in business, data, and project management has provided a solid foundation for TriTiCon's diverse services.

I’m Adam Walker a Biometrics consultant, and this is the Pharma Prescribed Podcast—where leaders, innovators, and hidden voices in healthcare open up. No soundbites. No spin. Just raw insight—one prescription at a time.

In an industry driven by data, protocols, and pressure, we rarely pause to ask the human questions: What drives us? What breaks us? And what truths live behind the titles we wear?

Belma Alispahic, Co-Founder and Chief Scientific Officer of AnalysisMode.

With a Master’s in Applied Biotechnology from Uppsala University and a track record of turning complexity into clarity, Belma is reshaping how we think about bioprocess development.

At AnalysisMode, she leads the charge behind SimCell, an AI-powered platform designed to accelerate bioprocess efficiency, reduce time-to-market, and future-proof pharmaceutical workflows.

Belma recently took the stage at the 9th Bioproduction Congress (BIOPC 2024) in France, where she shared her insights on “Future-Proofing with AI-Powered Bioprocess Development.” Her message was clear: AI isn’t optional—it’s essential for navigating the increasingly complex biopharma landscape.

This isn’t just about algorithms—it’s about empowering scientists to make smarter decisions, faster. Belma’s work is a testament to what happens when deep scientific expertise meets bold technological vision.